Advertisement
Heart, Lung and Circulation

Long-Term Ambulatory Intravenous Milrinone Therapy in Advanced Heart Failure

Published:October 10, 2022DOI:https://doi.org/10.1016/j.hlc.2022.09.004

      Background

      The role of intravenous (IV) inotropes in the treatment of ambulatory patients with advanced heart failure (HF) remains controversial.

      Methods

      This was a retrospective study of patients with advanced HF. Patients on home IV milrinone, who remained on it for at least 3 months, were included. We compared the data from 3 months before starting IV milrinone to 3 months after initiating therapy. A subset of patients who remained on milrinone for 6 months or longer was analysed separately.

      Results

      A total of 90 patients remained on continuous IV milrinone for 3 months, and 55 patients were treated for 6 months or longer. In both groups, improvements in cardiac index (1.86–2.25, p<0.001 and 1.9–2.38, p<0.0001), New York Heart Association (NYHA) class (3.32–2.76, p<0.0001 and 3.25–2.72, p=0.001), and liver function were noted. In the 6-month group, there was also a decrease in mean hospitalised days per patient (9.40 vs 4.12, p<0.001) and an improved tolerance of beta blocker therapy (83.3% vs 98.1%, p=0.006).

      Conclusion

      Long-term IV use of milrinone is associated with improvement in haemodynamics, functional class, tolerance of medical therapy, and decrease in hospitalised days.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • Butler J.
        • Casey Jr., D.E.
        • Drazner M.H.
        • et al.
        2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
        Circulation. 2013; 128: 1810-1852
        • Bui A.L.
        • Horwich T.B.
        • Fonarow G.C.
        Epidemiology and risk profile of heart failure.
        Nat Rev Cardiol. 2011; 8: 30-41
        • Mozaffarian D.
        • Benjamin E.J.
        • Go A.S.
        • Arnett D.K.
        • Blaha M.J.
        • Cushman M.
        • et al.
        Heart disease and stroke statistics-2016 update: a report from the American Heart Association.
        Circulation. 2016; 133: e38-e360
        • Allen L.A.
        • Stevenson L.W.
        • Grady K.L.
        • Goldstein N.E.
        • Matlock D.D.
        • Arnold R.M.
        • et al.
        Decision making in advanced heart failure: a scientific statement from the American Heart Association.
        Circulation. 2012; 125: 1928-1952
        • Hunt S.A.
        • Baker D.W.
        • Chin M.H.
        • Cinquegrani M.P.
        • Feldman A.M.
        • Francis G.S.
        • et al.
        ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America.
        Circulation. 2001; 104: 2996-3007
        • Sindone A.P.
        • Keogh A.M.
        • Macdonald P.S.
        • McCosker C.J.
        • Kaan A.F.
        Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy.
        Am Heart J. 1997; 134: 889-900
        • Harjai K.J.
        • Mehra M.R.
        • Ventura H.O.
        • Lapeyre Y.M.
        • Murgo J.P.
        • Stapleton D.D.
        • et al.
        Home inotropic therapy in advanced heart failure: cost analysis and clinical outcomes.
        Chest. 1997; 112: 1298-1303
        • Chua D.
        • Buttar A.
        • Kaan A.
        • Andrews H.
        • Kealy J.
        • Lam S.
        Home inotrope program for patients with end-stage heart failure awaiting heart transplant.
        Can J Hosp Pharm. 2011; 64: 292-293
        • Ponikowski P.
        • Voors A.A.
        • Anker S.D.
        • Bueno H.
        • Cleland J.G.F.
        • Coats A.J.S.
        • et al.
        2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
        Eur Heart J. 2016; 37: 2129-2200
        • Lee E.C.
        • McNitt S.
        • Martens J.
        • Bruckel J.T.
        • Chen L.
        • Alexis J.D.
        • et al.
        Long-term milrinone therapy as a bridge to heart transplantation: safety, efficacy, and predictors of failure.
        Int J Cardiol. 2020; 313: 83-88
        • Upadya S.
        • Lee F.A.
        • Saldarriaga C.
        • Verma S.
        • Sedrakyan A.
        • Nystrom K.
        • et al.
        Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure.
        J Heart Lung Transplant. 2004; 23: 466-472
        • Marius-Nunez A.L.
        • Heaney L.
        • Fernandez R.N.
        • Clark W.A.
        • Ranganini A.
        • Silber E.
        • et al.
        Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure.
        Am Heart J. 1996; 132: 805-808
        • Gorodeski E.Z.
        • Chu E.C.
        • Reese J.R.
        • Shishehbor M.H.
        • Hsich E.
        • Starling R.C.
        Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure.
        Circ Heart Fail. 2009; 2: 320-324
        • Hershberger R.E.
        • Nauman D.
        • Walker T.L.
        • Dutton D.
        • Burgess D.
        Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure.
        J Card Fail. 2003; 9: 180-187
        • Upadya S.
        • Lee F.A.
        • Saldarriaga C.
        • Verma S.
        • Sedrakyan A.
        • Nystrom K.
        • et al.
        Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure.
        J Heart Lung Transplant. 2004; 23: 466-472
        • Harjai K.J.
        • Mehra M.R.
        • Ventura H.O.
        • Lapeyre Y.M.
        • Murgo J.P.
        • Stapleton D.D.
        • et al.
        Home inotropic therapy in advanced heart failure.
        Chest. 1997; 112: 1298-1303
        • Acharya D.
        • Sanam K.
        • Revilla-Martinez M.
        • Hashim T.
        • Morgan C.J.
        • Pamboukian S.V.
        • et al.
        Infections, arrhythmias, and hospitalizations on home intravenous inotropic therapy.
        Am J Cardiol. 2016; 117: 952-956
        • Hauptman P.J.
        • Mikolajczak P.
        • George A.
        • Mohr C.J.
        • Hoover R.
        • Swindle J.
        • et al.
        Chronic inotropic therapy in end-stage heart failure.
        Am Heart J. 2006; 152 (1096.e1-e10968)
        • Brozena S.C.
        • Twomey C.
        • Goldberg L.R.
        • Desai S.S.
        • Drachman B.
        • Kao A.
        • et al.
        A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home.
        J Heart Lung Transplant. 2004; 23: 1082-1086
        • Snipelisky D.
        • Fudim M.
        • Perez A.
        • Nayor M.
        • Lever N.M.
        • Raymer D.S.
        • et al.
        Expected vs actual outcomes of elective initiation of inotropic therapy during heart failure hospitalization.
        Mayo Clin Proc Innov Qual Outcomes. 2020; 4: 529-536
        • Mody B.P.
        • Khan M.H.
        • Zaid S.
        • Ahn C.
        • Lloji A.
        • Aronow W.S.
        • et al.
        Survival with continuous outpatient intravenous inotrope therapy in the modern era.
        Am J Ther. 2020;
        • Harhash A.A.
        • Cassuto J.
        • Hussein A.
        • Achu E.
        • Zucker M.J.
        • Goldschmidt M.
        • et al.
        Safety of outpatient milrinone infusion in end-stage heart failure: ICD-level data on atrial fibrillation and ventricular tachyarrhythmias.
        Am J Med. 2020; 133: 857-864